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BACKGROUND: The current study was conducted to assess the impact of lymphovascular invasion on the survival of patients with
urothelial carcinoma of the renal pelvis. METHODS: Patients with urothelial carcinoma of the renal pelvis who underwent radical neph-
roureterectomy from 2010 through 2015 were identified in the National Cancer Data Base. Patients were characterized according to
demographic and clinical factors, including pathologic tumor stage and lymphovascular invasion. Associations with overall survival
were assessed through proportional hazards regression analysis. RESULTS: A total of 4177 patients were identified; 1576 had lympho-
vascular invasion. Patients with T3 disease and lymphovascular invasion had 5-year survival that was significantly worse than that of
patients with T3 disease without lymphovascular invasion (34.7% vs 52.6; P<.001 by the log-rank test), and approached that of
patients with T4 disease without lymphovascular invasion (34.7% vs 26.5%; P5.002). On multivariate analysis controlling for age,
comorbidities, grade, lymph node status, surgical margin status, race, sex, and chemotherapy administration, patients with T3 disease
and lymphovascular invasion also were found to have significantly worse survival compared with patients with T3 disease without
lymphovascular invasion (hazard ratio, 1.7; 95% confidence interval, 1.4-1.91). CONCLUSIONS: Lymphovascular invasion status is a key
prognostic marker that can stratify the risk of patients with pT3 upper tract urothelial carcinoma further. Patients with this pathologic
feature should be carefully considered for clinical trials exploring existing and novel therapies. Cancer 2018;124:2507-14. VC 2018 Amer-
ican Cancer Society.
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INTRODUCTION
The incidence of upper tract urothelial cancer (UTUC) has increased over recent decades, with 1.88 cases per 100,000
person-years reported in 2005.1 The American Joint Committee on Cancer (AJCC) seventh edition staging system classi-
fies UTUC into categories of worsening prognosis.2 Staging is based on the TNM system, with lymph node-negative and
metastasis-negative T1, T2, and T3 tumors assigned stages I, II, and III, respectively; T4 tumors and cases with positive
lymph nodes or metastases are assigned stage IV.
The AJCC system was constructed from available evidence that T classification is highly prognostic of survival out-
comes after surgical intervention.3,4 To our knowledge, due to low disease incidence, evidence to guide staging and prog-
nostication historically has been limited to small retrospective series. However, recent multi-institutional data-sharing
collaborations have published results reaffirming the centrality of T classification to prognosis with greater statistical
power.5-7
Interest also recently has emerged in lymphovascular invasion (LVI) as a prognostic modulator in patients with
UTUC. Several studies have found LVI to be an important predictor of survival outcomes, but again, to our knowledge
these largely have been confined to small retrospective series.8,9 Since 2010, the National Cancer Data Base (NCDB) has
collected data regarding LVI status for all newly diagnosed solid tumors, including renal pelvis cancer. Currently, data are
available for cases diagnosed through 2015. The broad nature of the data collected by the NCDB provides an excellent
opportunity to reassess the influence of LVI in UTUC and potentially affirm findings from previous studies.
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The objective of the current study was to determine
the impact of LVI on survival in patients with UTUC of
the renal pelvis, and to determine whether LVI status
might usefully inform the UTUC staging system by
improving the prognostic usefulness of T classification.
MATERIALS AND METHODS
The NCDB is a collaborative clinical registry between the
American College of Surgeons’ Commission on Cancer
and the American Cancer Society. Approximately 70% of
incident cancer cases in the United States from >1500
facilities are included.10
The database was queried for patients aged 18
years who were diagnosed with renal pelvic cancer from
January 1, 2010 to December 31, 2015. Only patients
who had undergone radical nephroureterectomy (RNU)
were included, both because this is the standard treatment
of UTUC of the renal pelvis and because patients
undergoing other treatment modalities lacked data
regarding pathologic staging and LVI status in high per-
centage. Patients with nonurothelial histology or rare uro-
thelial variant histology were excluded; the final cohort
had International Classification of Diseases for Oncology,
3rd Edition (ICD-O-3) codes 8120 or 8130. Patients also
were excluded due to: 1) prior malignancies; 2) known
metastatic disease; 3) unknown pathologic T or N classifi-
cation; 4) unknown LVI status; or 5) missing date ele-
ments needed to calculate follow-up or survival. The
selection process is summarized in Figure 1.
Statistical Analysis
Descriptive statistics were calculated. The Charlson-Deyo
Comorbidity Scores were grouped into categories of 0, 1,
or 2. A proportional hazards model was used to calcu-
late 2-year, 3-year, 4-year, and 5-year overall survival
(OS), stratified by pathologic T classification and LVI sta-
tus. Pathologic T classification was used because clinical T
classification was unavailable for a large percentage of
patients, and because of the significant upstaging that
occurs when clinical and pathologic T classifications are
compared.5,11 Patients listed as having N classification
N0 or Nx were both considered to be without known
lymph node-positive disease. Age-adjusted survival analy-
sis then was performed using proportional hazards regres-
sion and represented graphically in Kaplan-Meier plots.
Only patients with lymph node-negative disease were
included in both age-adjusted and age-unadjusted univar-
iate survival analyses. Survival differences between T clas-
sification and LVI groups were assessed using log-rank
comparisons in unadjusted analyses.
Multivariate proportional hazards survival analysis
then was performed, adjusting for demographic and clini-
cal covariates. Pathologic T classification and LVI status
were combined into a single composite category. Patients
with both N0 andN1 disease were included in the multi-
variate proportional hazards regression model; our inten-
tion was to demonstrate that LVI is an important
predictor of survival independent of lymph node status,
and is not merely a surrogate marker for lymph node posi-
tivity. Hazard ratios (HRs) were recalculated using differ-
ent T classification and LVI combinations as reference
groups. The model was repeated with subsequent primary
malignancies as a covariate (the number, site, and other
pathologic and clinical details of subsequent malignancies
were unavailable). Finally, a separate model was created
including T classification and LVI status as separate varia-
bles rather than a single composite variable. This allowed
for the inclusion of an interaction term between LVI
Figure 1. Selection criteria. LVI indicates lymphovascular inva-
sion; RNU, radical nephroureterectomy.
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status and lymph node positivity to further assess the
effect of LVI on survival independent of its relationship to
lymph node status.
All P values were the result of 2-sided tests and P val-
ues< .05 were considered to be statistically significant.
Statistics were performed with SAS statistical software
(version 9.4; SAS Institute Inc, Cary, North Carolina).
RESULTS
A total of 4177 patients in 963 different facilities met
selection criteria. Of these, 1576 patients (38%) were LVI
positive. Baseline demographics are summarized in Table
1. A total of 522 patients (12%) had known lymph node-
positive disease with a pathologic N classification of N1 to
N3. A total of 372 patients (9%) had positive surgical
margins. Chemotherapy, of any intent, was administered
during the treatment course of 959 patients (23.0%).
Subsequent primary malignancies were noted in 14% of
patients, including 13% of patients with a pathologic T
classification of T3 (15% of patients with pT3 LVI-
negative [LVI-] disease, and 12% of patients with pT3
LVI-positive [LVI1] disease). Among patients alive at the
time of last contact, the median follow-up was 922 days
(interquartile range, 513-1488 days). The median follow-
up for the entire cohort was 723 days (23.7 months).
During follow-up, 1529 patients (37%) died of any
cause; 2648 were alive at the time of last contact. Unad-
justed OS for the 3655 patients without known lymph
node-positive disease is shown in Table 2. The 95% confi-
dence intervals (95% CIs) for OS overlapped for the T1
LVI1 and T2 LVI- groups, for the T2 LVI1 and T3
LVI- groups, and for the T3 LVI1 and T4 LVI- groups.
The 95% CIs did not overlap for the T3 LVI- and T3
LVI1 groups. The OS rates were recalculated in an age-
adjusted fashion. These are shown in Supporting Table
S1. Age adjustment did not appear to alter the calculated
survival rates substantially and did not affect which groups
did or did not have overlapping CIs.
Among patients with pT3 disease without known
lymph node-positive disease, 8% had positive surgical
margins, including 3% of patients with pT3 LVI- disease
and 10% of patients with pT3 LVI1 disease. The 4-year
OS for patients with pT3 LVI- disease was 62.3 months
(95% CI, 58.5-66.4 months) for patients without positive
surgical margins and 40.1 months (95% CI, 23.5-68.3
months) for patients with positive surgical margins. The
4-year OS for patients with pT3 LVI1 disease was 43.6
months (95% CI, 39.1-48.7 months) for those without
positive margins and 12.5 months (95% CI, 5.9-26.8
months) for patients with positive surgical margins.
Among patients with pT3 LVI- disease, chemother-
apy was administered to 4% of patients before surgery and
20% of patients after surgery. Among patients with pT3
LVI1 disease, chemotherapy was administered to 4% of
patients before surgery and 33% of patients after surgery.
Age-adjusted proportional hazards survival for
patients without known lymph node-positive disease,
TABLE 1. Clinical and Pathologic Characteristics
(N54177)
Parameter No. of Patients %
Y of diagnosis
2010 681 16.3
2011 597 14.3
2012 690 16.5
2013 730 17.5
2014 815 19.5
2015 664 15.9
Age at diagnosis, y
18-39 32 0.8
40-49 142 3.4
50-59 564 13.5
60-69 1108 26.5
70-79 1384 33.1
80 948 22.7
Race
White (includes Hispanic) 3763 90.1
Black 215 5.1
Other/unknown 199 4.8
Sex
Male 2379 56.95
Female 1796 43.0
Other 2 .05
Charlson-Deyo Comorbidity Score
0 2854 68.3
1 956 22.9
2 367 8.8
WHO grade
Low 451 10.8
High 3495 83.7
Unknown 231 5.5
Pathologic T classification
1 1183 28.3
2 481 11.5
3 2076 49.7
4 437 10.5
Pathologic N classification
No known lymph node-positive disease 3655 87.5
Known lymph node-positive disease 522 12.5
Lymphovascular invasion
Present 1576 37.7
Absent 2601 62.3
Surgical margins
Positive 372 8.9
Negative 3754 89.9
Unknown 51 1.2
Chemotherapy administration
Yes 959 23.0
No 3077 73.7
Unknown 141 3.4
Status at time of last follow-up
Dead 1529 36.6
Alive 2648 63.4
Abbreviation: WHO, World Health Organization.
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stratified by pathologic T classification and LVI status, is
shown in Figure 2. Log-rank unadjusted comparisons
between selected pairs of groups without known lymph
node-positive disease are as follows: T1T2 LVI1 versus
T1T2 LVI-: P .0001; T1T2 LVI1 versus T3 LVI-:
P5 .6069; T1T2 LVI1 versus T3 LVI1 , P< .0001;
T1/T2 LVI1 versus T3 total (not shown), P< .0041; T3
LVI1 versus T3 LVI-, P< .0001; T3 LVI1 versus T4
LVI-, P5 .0019; T3 LVI1 versus T4 LVI1, P< .0001;
and T3 LVI1 versus T4 total, P< .0001.
The same graphical survival analysis was performed
with patients with T1 and T2 disease separated (see Sup-
porting Fig. S1). The T1 and T2 groups also were
graphed separately for greater visual clarity (see Support-
ing Fig. S2). The following additional log-rank compari-
sons were performed to further elucidate the relative
TABLE 2. OS in Patients Without Known Lymph Node-Positive Disease (N53655)
Cohort Patients 2-Year OS, % 95% CI 3-Year OS, % 95% CI 4-Year OS, % 95% CI 5-Year OS, % 95% CI
T1 LVI- 1065 92.5 90.8-94.2 86.5 84.0-89.0 80.4 77.3-83.7 74.8 70.9-79.0
T1 LVI1 105 83.5 76.4-91.3 77.4 69.0-87.0 73.9 64.7-84.4 64.8 52.8-79.5
T2 LVI- 349 89.3 85.8-92.9 79.4 74.3-84.9 70.3 63.9-77.4 58.9 50.9-68.1
T2 LVI1 102 76.4 68.0-85.9 59.9 49.7-72.1 52.2 41.5-65.7 44.4 33.1-59.6
T3 LVI- 989 76.9 74.1-79.8 67.4 64.1-70.9 60.9 57.2-64.9 52.6 48.2-57.4
T3 LVI1 768 56.7 53.1-60.6 48.3 44.4-52.5 40.7 36.5-45.3 34.7 30.1-40.0
T4 LVI- 72 35.4 25.2-49.7 30.5 20.5-45.4 26.5 16.3-43.0 26.5 16.3-43.0
T4 LVI1 205 25.5 19.9-32.7 16.6 11.7-23.5 12.6 8.0-19.7 9.1 4.8-17.3
Abbreviations: -, negative;1 , positive; 95% CI, 95% confidence interval; LVI, lymphovascular invasion; OS, overall survival.
Pathologic T classification was used.
Figure 2. Kaplan-Meier analysis of age-adjusted overall survival for patients without known lymph node-positive disease
(N53655). The number at risk for each group was as follows: T1/T2 lymphovascular invasion (LVI) negative (-), 1414 patients; T1/
T2 LVI positive (1), 207 patients; T3 LVI-, 989 patients; T3 LVI1, 768 patients; T4 LVI-, 72 patients; and T4 LVI1, 205 patients.
Path indicates pathologic.
Original Article
2510 Cancer June 15, 2018
impact of categories T1 and T2: T1 LVI1 versus T1
LVI-, P5 .0132; T1 LVI1 versus T2 LVI-, P5 .9000;
T2 LVI1 versus T2 LVI-, P5 .0007; and T2
LVI1 versus T3 LVI-, P5 .2229. Table 3 shows risk-
adjusted HRs for the effect of LVI and pathologic T classi-
fication on OS, controlling for demographic and patho-
logic cofactors in a multivariate proportional hazards
model. Substantially overlapping 95% CIs were observed
for the T1/T2 LVI1 and T3 LVI- groups, as well as for
the T3 LVI1 and T4 LVI- groups. The model also was
calculated with subsequent primary malignancy included
as a cofactor. Subsequent primary malignancy did not
affect survival (P5 .45), and we opted to omit this vari-
able from our primary reported model due to the lack of
specific detail available as previously noted. The analysis
also was repeated with patients with T1 and T2 disease
considered separately (see Supporting Table S2). The
95% CIs for the T2 LVI1 and T3 LVI- groups over-
lapped substantially, and the 95% CIs for the T1
LVI1 and T3 LVI- groups overlapped as well.
When T3 LVI- was set as the statistical referent, a
direct comparison of T3 LVI1 versus T3 LVI- disease
yielded an HR of 1.7 (95% CI, 1.5-2.0). Comparison of
T1T2 LVI1 versus T3 LVI- disease yielded an HR of 0.9
(95% CI, 0.7-1.1). Finally, when T3 LVI1was set as the
statistical referent, a direct comparison of T4 LVI- versus
T3 LVI1 disease yielded an HR of 1.4 (95% CI, 1.0-1.9).
An additional multivariate competing-risks survival
model was created to assess the interaction between LVI
and pathologic lymph node status. In this model, T classi-
fication and LVI were entered as independent variables,
rather than being combined into a composite variable as
shown in Figure 2 and Tables 2 and 3. T classification,
lymph node status, and LVI status all were independent
predictors of survival (P< .001 for each). The T3 classifi-
cation versus the T1/T2 classification carried an HR of
2.1 (95% CI, 1.8-2.5). The T4 classification versus the
T1/T2 classification carried an HR of 5.3 (95% CI, 4.0-
7.1-5.4). The interaction between LVI and lymph node
status was found to be statistically significant (P5 .003).
Table 4 shows the calculated HRs.
DISCUSSION
In the current study, LVI was found to be a key predictor
of poor prognosis in patients with UTUC of the renal pel-
vis treated with RNU. Patients with pathologic (p) T3,
LVI1 tumors represented individuals with a particularly
aggressive category of disease, with survival that was sub-
stantially worse than that of patients with pT3 LVI- dis-
ease and that approached that of patients with pT4 LVI-
disease. Survival differences between the pT3 LVI- and
pT3 LVI1 groups were both clinically meaningful (with
an 18% difference in the 5-year OS) and statistically
robust owing to the large sample size.
There is a known interaction between LVI and
lymph node positivity.12 In our multivariate competing
risks regression analysis, LVI maintained significance
when controlling for lymph node status. In addition, the
interaction term between LVI and lymph node status was
statistically significant when added to the model, indicat-
ing synergism of risk beyond the additive effect of the 2
variables. Both findings suggest that LVI has an
TABLE 3. Effect of Pathologic T Classification and
LVI on OS (N54177)
Group HR 95% CI P
T1/T2 LVI- Referent Referent
T1/T2 LVI1 1.8 1.4-2.3 <.001
T3 LVI- 2.1 1.8-2.5 <.001
T3 LVI1 3.7 3.1-4.3 <.001
T4 LVI- 5.3 4.0-7.1 <.001
T4 LVI1 7.1 5.8-8.7 <.001
Abbreviations: -, negative;1 , positive; 95% CI, 95% confidence interval;
HR, hazard ratio; LVI, lymphovascular invasion; OS, overall survival.
Multivariate competing risks regression analysis was adjusted for age, sex,
race, Charlson-Deyo Comorbidity Score, World Health Organization grade,
pathologic N classification, surgical margin status, and chemotherapy
administration. Cofactors with statistically significant independent effects
included older age (continuous) (HR, 1.03; 95% CI, 1.02-1.04), Charlson-
Deyo Comorbidity Score 2 (HR, 1.5; 95% CI, 1.3-1.8), pathologic
N1disease (HR, 1.5; 95% CI, 1.3-1.7), high grade (HR, 1.9; 95% CI, 1.5-
2.4), unknown grade (HR, 2.0; 95% CI, 1.4-2.7), positive surgical margins
(HR, 2.0; 95% CI, 1.8-2.4), unknown surgical margins (HR, 1.5; 95% CI,
1.0-2.2), and chemotherapy administration (HR, 0.8; 95% CI, 0.7-0.9).
TABLE 4. Effect of Interaction Between Pathologic
N Classification and LVI on OS (N54177)
N0 N1
HR 95% CI HR 95% CI
LVI 1.8 1.6-2.0 1.1 0.8-1.5
LVI- LVI1
HR 95% CI HR 95% CI
Lymph node positivity 2.2 1.6-2.9 1.3 1.1-1.6
Abbreviations: -, negative;1 , positive; 95% CI, 95% confidence interval;
HR, hazard ratio; LVI, lymphovascular invasion; OS, overall survival.
Multivariate competing risks regression analysis was adjusted for age, sex,
race, Charlson-Deyo Comorbidity Score, World Health Organization grade,
pathologic T classification, surgical margin status, and chemotherapy
administration. Cofactors with statistically significant independent effects
included older age (continuous) (HR, 1.03; 95% CI, 1.02-1.04), high grade
(HR, 1.9; 95% CI, 1.5-2.4), unknown grade (HR, 2.0; 95% CI, 1.4-2.7);
Charlson-Deyo Comorbidity Score 2 (HR, 1.5; 95% CI, 1.3-1.8), positive
surgical margins (HR, 2.1; 95% CI, 1.8-2.4), and chemotherapy administra-
tion (HR, 0.8; 95% CI, 0.7-0.9).
Lymphovascular Invasion in Renal Pelvic Cancer/Danzig et al
Cancer June 15, 2018 2511
independent impact on survival, distinct from its relation-
ship with lymph node status. The data from the current
study do suggest that the impact of LVI is substantially
greater in patients without known lymph node-positive
disease, which is consistent with prior evidence.9,12,13
This finding is rational given the significance of LVI as an
early step in tumor dissemination; it is logical that the
impact of LVI would be diminished when overt lymph
node spread is present.
We believe these data, particularly the strong effect
of LVI within the pT3 category, have implications for
pathologic staging. Although a reorganization of risk strat-
ification schema to merge patients with pT3 LVI1with
those with pT4 may be premature, a subcategorization of
the AJCC pT3 category into 2 categories based on the
presence of LVI may be reasonable. Although the current
study data also suggest a role for LVI in substratifying
other T classifications in addition to T3, the relatively
small number of patients in the T1/T2 and T4 subgroups
limited analytic power and limits the strength of the con-
clusions that can be drawn from the current study data.
However, it is notable that patients with category pT1/
T2, LVI1 disease had significantly worse prognosis com-
pared with their pT1/T2, LVI- counterparts. Further-
more, neither patients with pT1/T2 LVI1 disease nor
those with pT2 LVI1 disease had survival that differed
significantly from that of patients with pT3 LVI- tumors
on proportional hazards survival analysis. The relatively
smaller sample sizes in these subgroups preclude overly
strong conclusions; for this reason, we grouped pT1 and
pT2 together in the main analyses and included subanaly-
ses with pT1 and pT2 separated in the Supporting mate-
rial. Despite these caveats, the results are provocative, and
further investigation into the clinical behavior of these
subgroups is warranted, as is consideration of a role for
LVI in the selection of patients for adjuvant systemic
therapy.
LVI is known to be of prognostic significance in
patients with urothelial cell carcinoma of the bladder.14 In
a multicenter review of 750 patients, LVI predicted local
and distant recurrence, OS, and cause-specific survival
after cystectomy.13 In a 2013 meta-analysis of 21 studies,
LVI was found to predict recurrence-free survival, OS,
and cancer-specific survival after cystectomy.14 This rela-
tionship is observed in nonurothelial cell solid organ
tumors as well.15,16
Although prior studies have investigated the prog-
nostic significance of LVI in patients with UTUC, the
low incidence of UTUC has limited study quality; to our
knowledge, the majority of analyses are small,
retrospective, single-center series. Thus, in 2009, the
Upper Tract Urothelial Carcinoma Collaboration com-
bined data from 8 countries to produce a cohort of 1453
patients undergoing RNU for UTUC.9 LVI was found to
be present in approximately 24% of patients and was asso-
ciated with lower 5-year recurrence-free survival rate
(77% vs 44%) and cancer-specific survival rate (79% vs
47%). Another multicenter study from 2010 combined
data from 6 countries to produce a cohort of 762 different
patients undergoing RNU for UTUC.12 LVI was present
in 19.4% of patients and was associated with lower 5-year
recurrence-free survival rate (79.3% vs 45.1%) and
cancer-specific survival rate (82.1% vs 45.8%). That
group included LVI in a nomogram predicting disease
recurrence and survival after RNU.17 Other large collabo-
rative studies and a nearly 5000-patient meta-analysis fur-
ther supported the importance of LVI in predicting
survival in patients with UTUC.6,18
These findings have led investigators to suggest
using LVI status to risk stratify patients with UTUC after
RNU. Godfrey et al found LVI to be predictive of worse
survival in their cohort of 211 patients, and noted similar
survival between patients with T1 LVI1 disease and
patients with muscle-invasive LVI- disease.8 The authors
suggested consideration of including LVI in the TNM
system for UTUC pending larger studies. Data from the
current study, emanating from a broadly inclusive
national database, further support substratification of the
UTUCTNM system using LVI status.
Developments in pathologic staging and postoper-
ative risk stratification in oncology have important
implications for selecting patients for the receipt of adju-
vant therapy or participation in clinical trials. In UTUC,
there has been mixed evidence supporting adjuvant che-
motherapy in patients with high-risk (stage III-IV)
tumors.2,19-22 However, when only cisplatin-based regi-
mens are considered, disease-free survival and OS may
be improved,23 as observed in patients with urothelial
carcinoma of the bladder.24 The POUT trial, a random-
ized controlled trial of adjuvant chemotherapy versus
surveillance after RNU for patients with UTUC, opened
in 2012.25 Historically, neoadjuvant therapies for
UTUC have received greater emphasis than adjuvant
therapies due to the limitation on cisplatin administra-
tion to patients with reduced renal function after
RNU.26 However, novel nonplatinum agents such as
checkpoint inhibitors and immunotherapies currently
being tested in patients with urothelial carcinoma of the
upper urinary tract may expand our ability to deliver
adjuvant treatment to high-risk patients.27-29 This
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would elevate the usefulness of enhanced risk stratifica-
tion using variables such as LVI.
The strengths of the current study include its large
sample size and generalizability, capturing a majority of
incident cases of UTUC in the United States during the
study period, including cases managed at community cen-
ters. It is interesting to note that many prior studies repre-
sent institutional cohorts from tertiary referral centers,
with an inherent risk of selection bias. The prospective
nature of the data collection, and the NCDB’s rigorous
and standardized methodology for data collection, ensure
robust data quality and reduce the potential for measure-
ment bias.
Limitations of the current study include its limited
follow-up duration; however, prior studies have suggested
that a large percentage of UTUCmortality occurs early in
the disease course. Margulis et al found a median time to
cancer-specific mortality of 18.5 months.5 Underrepre-
sentation of certain subgroups is discussed above. No cen-
tralized pathologic rereview to verify LVI status was
performed; however, we contend that this reflects real-
world practice. Incomplete availability of data regarding
specific patient and pathologic factors resulted in a dimin-
ished cohort size and a less extensive set of covariates for
analytical models, which ultimately included age, sex,
race, Charlson-Deyo Comorbidity Score, World Health
Organization grade, pathologic N classification, surgical
margin status, and chemotherapy administration. Specific
pathologic features contributing to pT classification, such
as renal parenchyma invasion versus peripelvic fat involve-
ment in patients with pT3 disease, were unavailable, as
were data regarding tumor multifocality. Specifics of the
location and nature of subsequent malignancies were
unavailable, and we could not determine their clinical sig-
nificance or whether they represented unrelated malig-
nancies versus bladder or contralateral upper tract
recurrences.
The cohort in the current study was in some ways
unrepresentative of the US population, although not dis-
similar from previously reported populations with
UTUC; it was 90% white (including Hispanic) and
nearly 23% of the patients included were aged 80 years.
As noted, age adjustment did not meaningfully alter sur-
vival rates.
We also were limited in our ability to assess the
impact of chemotherapy within this cohort for 2 reasons.
The first is a low use rate of chemotherapy, which is reflec-
tive of real-world clinical practice.30 The second is insuffi-
cient data capture, because the NCDB identifies the
timing of chemotherapy but lacks sufficient detail to accu-
rately determine therapeutic intent.
A persistent difficulty in studying UTUC is the large
percentage of patients with pNx disease due to low rates of
lymphadenectomy during RNU (well below 50% in the
United States and Europe).31-33 We elected to categorize
patients with pN0 and pNx disease as those without
known lymph node-positive disease, in contrast to
patients with pN1 to pN3 disease, who we identified as
having lymph node-positive disease, because the alterna-
tive of excluding patients with pNx disease would artifi-
cially enrich the cohort for patients with lymph node-
positive disease and distort the data.
Conclusions
In the current study, LVI was able to risk stratify patients
after RNU for UTUC of the renal pelvis and identify
those at highest risk of death. Therefore, we believe LVI
represents a key factor in the selection of optimal candi-
dates for adjuvant treatment, clinical trials, or heightened
surveillance. Although to the best of our knowledge the
survival benefits of adjuvant chemotherapy for patients
with UTUC are incompletely proven, many novel agents
currently are in development, with demonstrated activity
in the metastatic setting and potential effectiveness in the
adjuvant setting as well.27-29 In the future, a wide pool of
effective and tolerable adjuvant therapy options will ren-
der a thorough understanding of each patient’s risk profile
more valuable. Pathologic features such as LVI may be
important contributors to that risk stratification.
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